NC
AUPH icon

nVerses Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

nVerses Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,440
Closed -$406K – 361
2025
Q4 		$406K Buy
+25,440
New +$361K 0.91% 4
2024
Q4 		– Sell
-2,400
Closed -$17.6K – 85
2024
Q3 		$17.6K Buy
+2,400
New +$14.9K 0.01% 822

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

nVerses Capital's AUPH Position: Q1 2026 in Review

nVerses Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 25,440 shares — an estimated $406K sold.

nVerses Capital first reported a position in AUPH in Q3 2024 and held it in 2 quarters. The position peaked at $406K in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • nVerses Capital reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • nVerses Capital sold 25,440 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $406K.
  • nVerses Capital first reported a position in Aurinia Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • nVerses Capital's Aurinia Pharmaceuticals position peaked at $406K in Q4 2025.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on nVerses Capital's 13F filing for Q1 2026, filed 13 May 2026.